Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	29.8	11.32	7.11	7.83	8.54
Cash & Short-Term Investments	29.8	11.32	7.11	7.83	8.54
Cash Growth	163.34%	59.23%	-9.27%	-8.24%	167.33%
Receivables	59.72	29.21	19.45	3.09	3.06
Inventory	21.26	16.24	12.93	9.55	6.74
Prepaid Expenses	1.33	0.98	0.52	1.03	0.53
Total Current Assets	112.11	57.74	40.01	21.51	18.86
Property, Plant & Equipment	13.01	14.1	14.61	10.44	6.98
Other Intangible Assets	-	0.29	0.29	0.29	0.47
Long-Term Deferred Tax Assets	7.82	18.37	22.16	2.17	2.17
Long-Term Deferred Charges	4.79	5.35	6.05	6.05	6.17
Other Long-Term Assets	0.56	0.55	0.53	0.43	0.5
Total Assets	138.29	96.39	83.65	40.9	35.15

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	6.05	2.96	2.71	2.45	1.43
Accrued Expenses	9.6	3.45	4.82	4.63	4.28
Short-Term Debt	-	4	4	-	-
Current Portion of Long-Term Debt	0.23	0.25	0.3	0.31	0.35
Current Portion of Leases	0.92	0.84	0.72	0.01	0.2
Current Income Taxes Payable	0.59	0.34	0.49	0.41	0.41
Current Unearned Revenue	-	0.01	0.01	0.01	0.01
Total Current Liabilities	17.39	11.84	13.05	7.83	6.69
Long-Term Debt	2.8	3.03	3.28	3.56	1.39
Long-Term Leases	1.87	2.8	3.44	-	0.84
Long-Term Unearned Revenue	-	-	0.01	0.02	0.03
Other Long-Term Liabilities	17.34	25.2	6.3	0.52	0.98
Total Liabilities	39.41	42.87	26.07	11.94	9.93

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	1.08	1.07	1.07	1.01	1.01
Additional Paid-In Capital	173.94	173.46	173.21	164.75	164.58
Retained Earnings	-75.83	-120.7	-116.39	-136.5	-140.06
Treasury Stock	-0.31	-0.31	-0.31	-0.31	-0.31
Total Common Equity	98.88	53.52	57.58	28.96	25.22
Shareholders' Equity	98.88	53.52	57.58	28.96	25.22
Total Liabilities & Equity	138.29	96.39	83.65	40.9	35.15

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	5.82	10.91	11.74	3.89	2.78
Net Cash (Debt)	23.98	0.4	-4.63	3.94	5.75
Net Cash Growth	5888.11%	-	-	-31.44%	606.63%
Net Cash Per Share	0.02	0.00	-0.00	0.00	0.01
Filing Date Shares Outstanding	1,077	1,068	1,068	1,014	1,011
Total Common Shares Outstanding	1,077	1,068	1,068	1,014	1,011
Working Capital	94.72	45.9	26.96	13.68	12.17
Book Value Per Share	0.09	0.05	0.05	0.03	0.02
Tangible Book Value	98.88	53.23	57.29	28.67	24.76
Tangible Book Value Per Share	0.09	0.05	0.05	0.03	0.02
Land	11.65	11.65	11.06	10.77	5.46
Machinery	16.63	15.71	15.02	14.24	13.85

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 5, 2026

Data Sources Report a data error